Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1‐year European observational study

Kraemer, Susanne A.; Chartier, F.; Augendre-Ferrante, B.; Psarra, Vassiliki; D’yachkova, Yulia; Beselin, Anke; Rouillon, Frédéric

doi:10.1002/hup.2224

Cited by 6 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the results are similar when conducting separate analyses for patients with schizophrenia and bipolar disorder. Fourth, we have not included medication in the analyses because all patients were taking two different formulations of the same agent and the main report from the original study found no major differences in outcomes between the two formulations [ 17 ]. Fifth, we have only analyzed some of the factors that can be related to patient outcomes (for example, clinical subtypes or family and social environment were not analyzed).…”

Section: Discussionmentioning

confidence: 99%

“…The specific ethics committees that approved the study are: (1) Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé (France); (2) Landesärztekammer Hessen Ethik-Kommission (Germany); (3) Papageorgiou Regional General Hospital of Thessaloniki (Greece). Further details about the study have been published previously [ 17 ].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study

Novick

Montgomery²,

Treuer

et al. 2015

BMC Psychiatry

Self Cite

View full text Add to dashboard Cite

BackgroundMany patients with schizophrenia and bipolar disorder have impaired insight and low medication adherence. The aim of this post hoc analysis was to explore the relationship between insight and medication adherence.MethodsWe included 903 patients with schizophrenia or bipolar disorder who participated in an observational study conducted in Europe on the outcomes of patients treated with two oral formulations of olanzapine over a 1-year period. Evaluations included Clinical Global Impression (CGI), Global Assessment of Functioning (GAF), insight (Scale to Assess Unawareness of Mental Disorder, SUMD) medication adherence (Medication Adherence Rating Scale, MARS), and therapeutic alliance (Working Alliance Inventory, WAI).ResultsMedication adherence was higher in bipolar patients (mean MARS score (SD) 6.5 (2.8) versus 5.8 (2.7) in schizophrenia; p < 0.001). Patients with schizophrenia had lower insight (i.e., SUMD item 1, unawareness of mental disorder, mean (SD) of 2.5 (1.3) in schizophrenia versus 1.9 (1.2) in bipolar, p < 0.001). Better insight was associated with higher adherence (Spearman Correlation Coefficient, SCC, ranging from 0.39 to 0.49 for the three SUMD general items, p < 0.0001 in all cases). Higher insight was related to a stronger therapeutic alliance (SCC ranging from 0.38 to 0.48, p < 0.0001). A path analysis revealed a positive impact of insight on adherence and alliance and that stronger alliance was related to lower clinical severity (lower CGI score).ConclusionInsight and adherence were found to be closely related. Insight impacts on the therapeutic alliance with mental health professionals. These factors are associated to treatment outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study

Novick

Montgomery²,

Treuer

et al. 2015

BMC Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…Details regarding the study design have been published previously 15–17. Briefly, data for this post hoc analysis were obtained from a prospective, observational (noninterventional), naturalistic, multicenter, multicountry study (France, Germany, and Greece) designed to compare medication adherence between two oral forms of olanzapine (ODT vs SOT) in patients with schizophrenia or bipolar disorder.…”

Section: Methodsmentioning

confidence: 99%

Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder

Novick¹,

Montgomery²,

Treuer³

et al. 2017

PPA

Self Cite

View full text Add to dashboard Cite

PurposeMedication nonadherence is common in the treatment of patients with severe mental illness and is a frequent cause of relapse. Different formulations have been developed in an effort to improve medication adherence. The aim of this study was to explore whether there are differential clinical outcomes between two different formulations of olanzapine (orodispersible tablets [ODTs] vs standard oral tablets [SOT]) for the treatment of nonadherent patients with schizophrenia or bipolar disorder.MethodsData for this analysis were from an observational study conducted in Europe (N=903). Adult schizophrenia and bipolar disorder patients in outpatient settings who initiated or changed to either olanzapine ODT or SOT according to physician decision within the last 45 days were eligible for enrollment. The follow-up period was 1 year. Of the 903 participants, 266 nonadherent patients (Medication Adherence Rating Scale score 0–4 at baseline) were included in the analysis. Clinical outcomes of interest were: 1) hospitalization and 2) relapse identified by the participating psychiatrist or hospitalization. An adjusted logistic regression model was fitted.ResultsPatients taking ODT had more severe illness at baseline (P<0.001) as assessed with the Clinical Global Impression with mean (standard deviation [SD]) scores of ODT 4.63 (1.03) and SOT 4 (1.16). In the regression models adjusted for potential confounders, patients taking ODT had significantly lower odds for hospitalization (odds ratio =0.355; 95% confidence interval =0.13–0.974) and relapse or hospitalization (odds ratio =0.368; 95% confidence interval =0.183–0.739), respectively.ConclusionNonadherent patients with schizophrenia or bipolar disorder treated with the orodispersible formulation were less likely to be hospitalized or suffer relapse compared to those patients taking the standard oral coated tablets.

show abstract

Poor Adherence to Antipsychotic Medication in People with Schizophrenia: Diffusion, Consequences and Contributing Factors

Sacchetti¹,

Vita²

2013

Adherence to Antipsychotics in Schizophrenia

View full text Add to dashboard Cite

Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1‐year European observational study

Abstract: No significant difference was seen between discontinuation rates of the two formulations. Higher baseline severity was associated with a lower discontinuation rate.

Cited by 6 publications

References 33 publications

Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study

Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study

Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder

Poor Adherence to Antipsychotic Medication in People with Schizophrenia: Diffusion, Consequences and Contributing Factors

Contact Info

Product

Resources

About